Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 6/2011

01-12-2011 | Genetics (Jose C. Florez, Section Editor)

Gene × Environment Interactions in Type 2 Diabetes

Author: Paul W. Franks

Published in: Current Diabetes Reports | Issue 6/2011

Login to get access

Abstract

People vary genetically in their susceptibility to the effects of environmental risk factors for many diseases. Genetic variation also underlies the extent to which people respond appropriately to clinical therapies. Defining the basis to the interactions between the genome and the environment may help elucidate the biologic basis to diseases such as type 2 diabetes, as well as help target preventive therapies and treatments. This review examines 1) some of the most current evidence on gene × environment interactions in relation to type 2 diabetes; 2) outlines how the availability of information on gene × environment interactions might help improve the prevention and treatment of type 2 diabetes; and 3) discusses existing and emerging strategies that might enhance our ability to detect and exploit gene × environment interactions in complex disease traits.
Literature
1.
2.
Fox CS, Coady S, Sorlie PD, D’Agostino Sr RB, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115:1544–50.PubMedCrossRef
3.
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.PubMedCrossRef
4.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRef
5.
Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMedCrossRef
6.
Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.PubMedCrossRef
7.
Baron AL. Facet number in Drosophila melanogaster as influenced by certain genetic and environmental factors. J Exp Zool. 1935;70:461–90.CrossRef
8.
Jacob F, Monod J. Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol. 1961;3:318–56.PubMedCrossRef
9.
10.
•• The InterAct Consortium. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. Diabetologia. 2011;54(9):2272–82. The InterAct Study is a European-based nested case-cohort study designed for the detection of gene x lifestyle interactions in type 2 diabetes. The study is the largest and most comprehensive of its kind to date involving around 12,500 incident cases and 16,000 non-cases selected from a background population of around a third of a million people. CrossRef
11.
Prentice AM. Early influences on human energy regulation: thrifty genotypes and thrifty phenotypes. Physiol Behav. 2005;86:640–5.PubMedCrossRef
12.
• Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the ‘drifty gene’ hypothesis. Int J Obes. 2008;32:1611–7. This is an opinion piece arguing against the selection of so-called thrifty genes in the human gene pool. CrossRef
13.
Bouchard C, Rankinen T. Individual differences in response to regular physical activity. Med Sci Sports Exerc. 2001;33:S446–51. discussion S452-443.PubMedCrossRef
14.
Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D’Agostino Sr RB. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068–74.PubMedCrossRef
15.
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220–32.PubMedCrossRef
16.
Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208–19.PubMedCrossRef
17.
de Miguel-Yanes JM, Shrader P, Pencina MJ, Fox CS, Manning AK, Grant RW, et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care. 2011;34:121–5.PubMedCrossRef
18.
Lu Q, Elston RC. Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes. Am J Hum Genet. 2008;82:641–51.PubMedCrossRef
19.
Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflammation and chronic disease. Nature. 2008;454:463–9.PubMedCrossRef
20.
Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature. 2002;418:797–801.PubMedCrossRef
21.
Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, et al. Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. Diabetes. 2003;52:2874–81.PubMedCrossRef
22.
Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA. 2003;100:8466–71.PubMedCrossRef
23.
Franks PW, Loos RJ. PGC-1alpha gene and physical activity in type 2 diabetes mellitus. Exerc Sport Sci Rev. 2006;34:171–5.PubMedCrossRef
24.
Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, et al. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes. Diabetologia. 2006;49:501–5.PubMedCrossRef
25.
• Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–89. This is a recent report from the DIAGRAM+ consortium summarizing the findings from meta-analyses of GWAS data. The report outlines association signals for more than 30 replicated loci. PubMedCrossRef
26.
Franks PW, Barroso I, Luan J, Ekelund U, Crowley VEF, Sandhu MS, et al. Wareham NJ PGC-1a genotype modifies the association of volitional energy expenditure with VO2max. Med Sci Sports Exerc. 2003;35(12):1998–2004.PubMedCrossRef
27.
Ridderstråle M, Johansson LE, Rastam L, Lindblad U. Increased risk of obesity associated with the variant allele of the PPARGC1A Gly482Ser polymorphism in physically inactive elderly men. Diabetologia. 2006;49(3):496–500.PubMedCrossRef
28.
Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O’Rahilly S, et al. Wareham NJ PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge. Diabetologia. 2007;50(3):569–73.PubMedCrossRef
29.
Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene (PGC-1alpha) is not associated with type 2 diabetes mellitus or body mass index among Hispanic and non Hispanic Whites from Colorado. Exp Clin Endocrinol Diabetes. 2007;115(4):268–75.PubMedCrossRef
30.
Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab. 2007;92(5):1827–33.PubMedCrossRef
31.
Brito EC, Vimaleswaran VK, Brage S, Andersen LB, Sardinha LB, Wareham NJ, et al. PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of main genetic effects and gene x environment interactions in children from the European Youth Heart Study. Diabetologia. 2009;52(4):609–13.PubMedCrossRef
32.
Bray MS, Hagberg JM, Perusse L, Rankinen T, Roth SM, Wolfarth B, et al. The human gene map for performance and health-related fitness phenotypes: the 2006–2007 update. Med Sci Sports Exerc. 2009;41:35–73.PubMed
33.
Kooperberg C, Leblanc M. Increasing the power of identifying gene x gene interactions in genome-wide association studies. Genet Epidemiol. 2008;32:255–63.PubMedCrossRef
34.
• Brito EC, Lyssenko V, Renstrom F, Berglund G, Nilsson PM, Groop L, et al. Previously associated type 2 diabetes variants may interact with physical activity to modify the risk of impaired glucose regulation and type 2 diabetes: a study of 16,003 Swedish adults. Diabetes. 2009;58:1411–8. This is a comprehensive assessment of genetic variation at the PPARGC1A locus in relation to cardiovascular and metabolic quantitative traits and their interactions with physical activity in more than 2000 European school children. PubMedCrossRef
35.
Moore AF, Jablonski KA, McAteer JB, Saxena R, Pollin TI, Franks PW, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;57:2503–10.PubMedCrossRef
36.
• Ruchat SM, Rankinen T, Weisnagel SJ, Rice T, Rao DC, Bergman RN, et al. Improvements in glucose homeostasis in response to regular exercise are influenced by the PPARG Pro12Ala variant: results from the HERITAGE Family Study. Diabetologia. 2010;53:679–89. This is an analysis of eight variants in seven type 2 diabetes genes in relation to a range of quantitative traits derived from an intravenous glucose tolerance test before and after 20 weeks of aerobic conditioning exercise. PubMedCrossRef
37.
Luan J, Browne PO, Harding AH, Halsall DJ, O’Rahilly S, Chatterjee VK, et al. Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes. 2001;50:686–9.PubMedCrossRef
38.
Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, et al. Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet. 2003;12:2923–9.PubMedCrossRef
39.
Franks PW, Mesa JL, Harding AH, Wareham NJ. Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis. 2007;17:104–24.PubMedCrossRef
40.
•• Palla L, Higgins JP, Wareham NJ, Sharp SJ. Challenges in the use of literature-based meta-analysis to examine gene-environment interactions. Am J Epidemiol. 2010;171:1225–32. This is a paper that discusses the practical and methodologic limitations of conducting literature-based meta-analyses of GEI studies. PubMedCrossRef
41.
Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM. Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado. Metabolism: clinical and experimental. 2007;56:388–93.CrossRef
42.
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, et al. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab. 2007;92:1502–9.PubMedCrossRef
43.
Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes. 2002;51:2581–6.PubMedCrossRef
44.
Kilpelainen TO, Lakka TA, Laaksonen DE, et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc. 2008;40:25–33.PubMed
45.
Frayling TM, Timpson NJ, Weedon MN, et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316:889–94.PubMedCrossRef
46.
Andreasen CH, Stender-Petersen KL, Mogensen MS, et al. Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation. Diabetes. 2008;57:95–101.PubMedCrossRef
47.
Rampersaud E, Mitchell BD, Pollin TI, et al. Physical activity and the association of common FTO gene variants with body mass index and obesity. Arch Intern Med. 2008;168:1791–7.PubMedCrossRef
48.
Franks PW, Jablonski KA, Delahanty LM, McAteer JB, Kahn SE, Knowler WC, et al. Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2008;51:2214–23.PubMedCrossRef
49.
•• Nettleton JA, McKeown NM, Kanoni S, et al. Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care. 2010;33:2684–91. This is a large-scale meta-analysis of data on gene x nutrient (dietary whole grains) interactions in relation to fasting insulin and glucose concentrations. The study identified a variant at the GCKR locus that showed tentative evidence of gene x nutrient interactions. PubMedCrossRef
50.
•• Kanoni S, Nettleton JA, Hivert MF, et al. Total zinc intake may modify the glucose-raising effect of a zinc transporter (SLC30A8) variant: a 14-cohort meta-analysis. diabetes 2011 (epublished Aug 1). This is a large-scale meta-analysis of data on gene x zinc (dietary and supplemental) interactions in relation to fasting insulin and glucose concentrations. The study identified a variant at the SLC30A8 locus, a gene encoding a zinc transporter, that showed tentative evidence of gene x nutrient interactions.
51.
Rutter GA. Think zinc: new roles for zinc in the control of insulin secretion. Islets. 2010;2:49–50.PubMedCrossRef
52.
• Franks PW, Brito EC. Interaction between exercise and genetics in type 2 diabetes mellitus: an epidemiological perspective. In: Roth SM, Pescatello L, editors. Exercise genomics: molecular & translational medicine. Springer Science: Clifton; 2011. This is a systematic review of literature on gene x exercise interactions related to type 2 diabetes.
53.
•• Franks PW, Nettleton JA. Invited commentary: gene X lifestyle interactions and complex disease traits—inferring cause and effect from observational data, sine qua non. Am J Epidemiol. 2010;172:992–7; discussion 998–999. This is an editorial commentary discussing causal inference in epidemiologic studies of gene x lifestyle interactions.
54.
• Moore JH, Asselbergs FW, Williams SM. Bioinformatics challenges for genome-wide association studies. Bioinformatics. 2010;26:445–55. This is an overview of the limitations of GWAS, including discussion of why such studies are poorly suited to the discovery of GEIs. PubMedCrossRef
55.
•• Pare G, Cook NR, Ridker PM, Chasman DI. On the use of variance per genotype as a tool to identify quantitative trait interaction effects: a report from the Women’s Genome Health Study. PLoS Genet. 2010;6:e1000981. This is a paper that describes and tests an agnostic method for the detection of GEIs. The authors identified several novel interactions using this method in the Women’s Genome Health Study. PubMedCrossRef
56.
Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, et al. Rationale, design, and methodology of the Women’s Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem. 2008;54:249–55.PubMedCrossRef
57.
Boks MP, Schipper M, Schubart CD, Sommer IE, Kahn RS, Ophoff RA. Investigating gene environment interaction in complex diseases: increasing power by selective sampling for environmental exposure. Int J Epidemiol. 2007;36:1363–9.PubMedCrossRef
58.
Wong MY, Day NE, Luan JA, Wareham NJ. Estimation of magnitude in gene-environment interactions in the presence of measurement error. Stat Med. 2004;23:987–98.PubMedCrossRef
59.
•• Manning AK, LaValley M, Liu CT, Rice K, An P, Liu Y, et al. Meta-analysis of gene-environment interaction: joint estimation of SNP and SNP x environment regression coefficients. Genet Epidemiol. 2011;35:11–8. This is a paper describing and applying an adaptation of the 2 d.f. method for jointly studying interactions (between a genetic and environmental risk factor) and genetic main effects. The method, known as JMA, along with others were tested using data from multiple cohorts in which PPARG had been tagged and these variants tested for interactions with BMI on fasting insulin levels. PubMedCrossRef
60.
• Chatterjee N, Wacholder S. Invited commentary: efficient testing of gene-environment interaction. Am J Epidemiol. 2009;169:231–3; discussion 234–235. This is a paper describing methods upon which Manning et al. [59••] builds.
61.
Kraft P, Yen YC, Stram DO, Morrison J, Gauderman WJ. Exploiting gene-environment interaction to detect genetic associations. Hum Hered. 2007;63:111–9.PubMedCrossRef
62.
Becker BJ, Wu MJ. The synthesis of regression slopes in meta-analysis. Stat Sci. 2007;22:414–29.CrossRef
63.
Wareham NJ, Franks PW, Harding AH. Establishing the role of gene-environment interactions in the etiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2002;31:553–66.PubMedCrossRef
64.
Franks PW. The interaction of genetic factors and physical activity energy expenditure in the aetiology of the metabolic syndrome. In: Department of community medicine. Cambridge, Cambridge University; 2003, p. 490.
65.
Renström F, Payne F, Nordström A, Brito EC, Rolandsson O, Hallmans G, et al. the GIANT consortium. Replication and extension of genome-wide association study results for obesity in 4,923 adults from Northern Sweden. Hum Mol Genet. 2009;18(8):1489–96.PubMedCrossRef
Metadata
Title
Gene × Environment Interactions in Type 2 Diabetes
Author
Paul W. Franks
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 6/2011
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-011-0224-9

Other articles of this Issue 6/2011

Current Diabetes Reports 6/2011 Go to the issue

Psychosocial Aspects (Korey Hood, Section Editor)

Mobile Intervention Design in Diabetes: Review and Recommendations

Psychosocial Aspects (Korey Hood, Section Editor)

Methodological Issues in the Assessment of Diabetes Treatment Adherence

Letter to the Editor

Reply to the letter by P. Guillausseau Regarding “Sulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yet Closed”

Genetics (Jose C. Florez, Section Editor)

Neonatal Diabetes: An Expanding List of Genes Allows for Improved Diagnosis and Treatment

Clinical Trial Report

Taking Evidence-Based Coping Skills Training to the Internet

Clinical Trial Report

Does Metformin Work for Everyone? A Genome-wide Association Study for Metformin Response
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits